Mohsin Khalique
Child & Adolescent Psychiatry · San Ramon, CANPI 1124083589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 914 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 914 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$4K
- Alkermes, Inc.$2K
- AbbVie$2K
- Johnson & Johnson$2K
- Lundbeck LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $8K from 23 others
What the payments were for
- Consulting fees$6083%
- Food & beverage$18,53895%
- Education$3912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 119 | $3,516 |
| Alkermes, Inc. | 77 | $1,918 |
| AbbVie(2 entities) | 108 | $1,662 |
| Johnson & Johnson | 55 | $1,599 |
| Lundbeck LLC | 100 | $1,546 |
| Takeda Pharmaceuticals U.S.A., Inc. | 111 | $1,534 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $1,369 |
| Axsome Therapeutics, Inc. | 31 | $1,053 |
| Neurocrine Biosciences, Inc. | 34 | $809 |
| E.r. Squibb & Sons, L.L.C. | 23 | $768 |
| Sunovion Pharmaceuticals Inc. | 30 | $575 |
| Corium, LLC | 41 | $513 |
| Vanda Pharmaceuticals Inc. | 26 | $470 |
| Teva Pharmaceuticals USA, Inc. | 19 | $453 |
| Bausch Health US, LLC | 24 | $430 |
| Tris Pharma Inc | 13 | $253 |
| Supernus Pharmaceuticals, Inc. | 6 | $158 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $131 |
| Ironshore Pharmaceuticals Inc. | 3 | $127 |
| Shire North American Group Inc | 10 | $124 |
| Neuronetics, Inc. | 2 | $114 |
| Adlon Therapeutics L.p. | 5 | $111 |
| Collegium Pharmaceutical, Inc. | 4 | $61 |
| Neos Therapeutics, LP | 4 | $61 |
| Merck | 3 | $49 |
| Biogen | 3 | $41 |
| Eisai Inc. | 2 | $33 |
| Almatica Pharma LLC | 1 | $31 |
| Abbott | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$1,439
- LYBALVI$925
- Auvelity$487
- ARISTADA$458
- CAPLYTA$381
- TRINTELLIX$314
- SPRAVATO$243
- COBENFY$215
- ABILIFY MAINTENA$124
- Fanapt$123
- ARISTADA INITIO$115
- VRAYLAR$107
How this compares
$19,536 in reported general payments places this provider in the 95th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $95,047 |
| Abilify AsimtufiiAripiprazole | 15 | $90,077 |
| RexultiBrexpiprazole | 11 | $15,087 |
| Adderall XrDextroamphetamine/Amphetamine | 22 | $9,141 |
| BelsomraSuvorexant | 12 | $5,238 |
| Lurasidone Hcl | 13 | $3,795 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 29 | $2,576 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $2,096 |
| Divalproex Sodium ErDivalproex Sodium | 30 | $1,607 |
| Duloxetine Hcl | 35 | $1,074 |
| Bupropion XlBupropion Hcl | 26 | $948 |
| Gabapentin | 61 | $942 |
| Buspirone Hcl | 19 | $939 |
| Alprazolam | 34 | $853 |
| Lamotrigine | 41 | $786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti | $3,516 | $105,16326 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $809 | $95,04712 claims |
| MerckBelsomra | $49 | $5,23812 claims |
| Almatica Pharma LLCSertraline Hcl | $31 | $12435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 child & adolescent psychiatry providers in California.
Other child & adolescent psychiatry in San Ramon
- Kevin CoxOjai$2.9M
- Sukhjit BrarFresno$283K
- Manpreet SinghSacramento$104K
- Ihab SolimanCorona del Mar$93K
- Syed NaqviLos Angeles$69K
- Ellen HeynemanSan Diego$62K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
- Mansoor ZuberiWalnut Creek$16K
- Michael McManusSan Diego$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.